Amgen-23

• CAT Number: I043402
• CAS Number: 1448706-15-7
• Molecular Formula: C23H25Cl2N3O2S
• Molecular Weight: 478.43
• Purity: ≥95%
• Synonyms: (2R,4S)-1-[2-[4-[[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]amino]phenyl]ethyl]-2-(hydroxymethyl)piperidin-4-ol
• InChI: InChI=1S/C23H25Cl2N3O2S/c24-20-6-3-16(11-21(20)25)22-14-31-23(27-22)26-17-4-1-15(2-5-17)7-9-28-10-8-19(30)12-18(28)13-29/h1-6,11,14,18-19,29-30H,7-10,12-13H2,(H,26,27)/t18-,19+/m1/s1
• InChIKey: SQJKFWCRPARYPY-MOPGFXCFSA-N
• SMILES: C1CN([C@H](C[C@H]1O)CO)CCC2=CC=C(C=C2)NC3=NC(=CS3)C4=CC(=C(C=C4)Cl)Cl

Amgen-23（Cat No.:I043402）is an investigational monoclonal antibody being studied for its potential therapeutic applications, particularly in the treatment of autoimmune diseases or inflammatory conditions. It works by targeting specific cytokines or receptors involved in immune system regulation, helping to modulate excessive immune responses that cause inflammation and tissue damage. Amgen-23 is being evaluated in clinical trials for diseases such as rheumatoid arthritis, psoriasis, or other immune-related disorders. Ongoing research aims to assess its efficacy, safety, and long-term effects, potentially offering a new treatment option for patients with autoimmune diseases.